NCT01297582View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2011

Conditions
Healthy Adult Subjects
Interventions
DRUG

ONO-6950

1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study

DRUG

ONO-6950

1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study

Trial Locations (1)

33025

Miramar Clinical Site, Miramar

Sponsors

Lead Sponsor

Ono Pharma USA Inc
All Listed Sponsors
lead

Ono Pharma USA Inc

INDUSTRY

NCT01297582 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter